193 related articles for article (PubMed ID: 36896312)
1. Hot topics in pancreatic cancer management.
Caputo D
World J Gastrointest Surg; 2023 Feb; 15(2):121-126. PubMed ID: 36896312
[TBL] [Abstract][Full Text] [Related]
2. Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts.
Link KH; Leder G; Formentini A; Fortnagel G; Kornmann M; Schatz M; Beger HG
Gan To Kagaku Ryoho; 1999 Jan; 26(1):10-40. PubMed ID: 9987495
[TBL] [Abstract][Full Text] [Related]
3. Effect of neoadjuvant radiotherapy on survival of non-metastatic pancreatic ductal adenocarcinoma: a SEER database analysis.
Wang D; Liu C; Zhou Y; Yan T; Li C; Yang Q; Xu Y; Zhao L; Pei Q; Tan F; Güngör C; Li Y
Radiat Oncol; 2020 May; 15(1):107. PubMed ID: 32404114
[TBL] [Abstract][Full Text] [Related]
4. Update on the management of pancreatic cancer: surgery is not enough.
Ansari D; Gustafsson A; Andersson R
World J Gastroenterol; 2015 Mar; 21(11):3157-65. PubMed ID: 25805920
[TBL] [Abstract][Full Text] [Related]
5. Nanotechnology and pancreatic cancer management: State of the art and further perspectives.
Caputo D; Pozzi D; Farolfi T; Passa R; Coppola R; Caracciolo G
World J Gastrointest Oncol; 2021 Apr; 13(4):231-237. PubMed ID: 33889275
[TBL] [Abstract][Full Text] [Related]
6. Neo-adjuvant therapy for pancreatic cancer: hope for the future.
Borazanci E; Sckolnik S; Amini A
Expert Rev Gastroenterol Hepatol; 2019 Jun; 13(6):579-589. PubMed ID: 30979348
[TBL] [Abstract][Full Text] [Related]
7. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic Ductal Adenocarcinoma (PDAC) Organoids: The Shining Light at the End of the Tunnel for Drug Response Prediction and Personalized Medicine.
Frappart PO; Hofmann TG
Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 32987786
[TBL] [Abstract][Full Text] [Related]
9. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
10. Perioperative, Spatiotemporally Coordinated Activation of T and NK Cells Prevents Recurrence of Pancreatic Cancer.
Brooks J; Fleischmann-Mundt B; Woller N; Niemann J; Ribback S; Peters K; Demir IE; Armbrecht N; Ceyhan GO; Manns MP; Wirth TC; Kubicka S; Bernhardt G; Smyth MJ; Calvisi DF; Gürlevik E; Kühnel F
Cancer Res; 2018 Jan; 78(2):475-488. PubMed ID: 29180478
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study.
Kung HC; Yu J
MedComm (2020); 2023 Apr; 4(2):e216. PubMed ID: 36814688
[TBL] [Abstract][Full Text] [Related]
12. Perspectives in the treatment of pancreatic adenocarcinoma.
Cid-Arregui A; Juarez V
World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
[TBL] [Abstract][Full Text] [Related]
13. The role of intraperitoneal chemotherapy in the surgical management of pancreatic ductal adenocarcinoma: a systematic review.
Brind'Amour A; Webb M; Parapini M; Sidéris L; Segedi M; Chung SW; Chartier-Plante S; Dubé P; Scudamore CH; Kim PTW
Clin Exp Metastasis; 2021 Apr; 38(2):187-196. PubMed ID: 33486670
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care.
Hamad A; Brown ZJ; Ejaz AM; Dillhoff M; Cloyd JM
World J Gastroenterol; 2021 Jul; 27(27):4383-4394. PubMed ID: 34366611
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma.
Silvestris N; Longo V; Cellini F; Reni M; Bittoni A; Cataldo I; Partelli S; Falconi M; Scarpa A; Brunetti O; Lorusso V; Santini D; Morganti A; Valentini V; Cascinu S
Crit Rev Oncol Hematol; 2016 Feb; 98():309-24. PubMed ID: 26653573
[TBL] [Abstract][Full Text] [Related]
16. Diverse and precision therapies open new horizons for patients with advanced pancreatic ductal adenocarcinoma.
Bai RL; Wang NY; Zhao LL; Zhang YF; Cui JW
Hepatobiliary Pancreat Dis Int; 2022 Feb; 21(1):10-24. PubMed ID: 34538570
[TBL] [Abstract][Full Text] [Related]
17. Pharmacotherapeutic options for pancreatic ductal adenocarcinoma.
Sardar M; Recio-Boiles A; Mody K; Karime C; Chandana SR; Mahadevan D; Starr J; Jones J; Borad M; Babiker H
Expert Opin Pharmacother; 2022 Dec; 23(18):2079-2089. PubMed ID: 36394449
[TBL] [Abstract][Full Text] [Related]
18. Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma.
Gray S; de Liguori Carino N; Radhakrishna G; Lamarca A; Hubner RA; Valle JW; McNamara MG
Eur J Surg Oncol; 2022 Jun; 48(6):1198-1208. PubMed ID: 35264307
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC-GS/GA-rP2, CSGO-HBP-015).
Yamada D; Kobayashi S; Takahashi H; Akita H; Yamada T; Asaoka T; Shimizu J; Takeda Y; Yokoyama S; Tsujie M; Tomokuni A; Tanemura M; Morimoto O; Murakami M; Kim Y; Nakahira S; Hama N; Sugimoto K; Hashimoto K; Doki Y; Eguchi H
Trials; 2021 Aug; 22(1):568. PubMed ID: 34446057
[TBL] [Abstract][Full Text] [Related]
20. Resection and radiochemotherapy of pancreatic cancer--the future?
Link KH; Formentini A; Leder G; Fortnagel G; Sartori N; Schatz M; Beger HG
Langenbecks Arch Surg; 1998 Apr; 383(2):134-44. PubMed ID: 9641886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
